Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

A Merck drug developed to prevent disease from respiratory syncytial virus (RSV) in infants has won FDA ... vaccine comprised of an engineered version of RSV F protein antigen. It was first ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...

CHARLOTTE — The Food and Drug Administration approved a new vaccine to help protect infants from RSV on Monday. The treatment ...

(Reuters) -The U.S. Food and Drug Administration on Monday approved ... RSV — an RSV vaccine given to the mother during pregnancy or an RSV antibody given to the baby. Merck expects the drug's ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants ... their mothers did not receive a maternal RSV vaccine.

Merck said in a release that it expects orders for the shot to begin in July, with shipments delivered before the virus starts to spread widely. The approval gives doctors a new option for ...